- Case report
- Open Access
- Open Peer Review
Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation
© The Author(s). 2017
- Received: 10 January 2017
- Accepted: 14 July 2017
- Published: 24 July 2017
Nephrogenic systemic fibrosis (NSF) is a complication of the gadolinium-based contrast agent used in imaging studies. It is typically characterised by hard, erythematous and indurated skin plaques with surrounding subcutaneous oedema. Distinct papules and subcutaneous nodules can also be seen. Fibrocytes in NSF are immunohistochemically positive for CD34.
We present a case of NSF occurred after gadolinium exposure in which the initial presentation mimics an erythema nodosum (EN)-like picture. An initial skin biopsy showed EN. Subsequently the patient developed progressive skin and joints contracture. A repeated skin biopsy done three months later confirmed the diagnosis of NSF. As far as we are aware, this is the second reported case of NSF that mimicked the presentation of EN in the early phase of the disease.
The appearance of EN-like disease can be one of the early manifestations of NSF. We hope that early recognition of this unusual presentation can alert the physician or nephrologist to the potential diagnosis of NSF.
- Nephrogenic systemic fibrosis
- Erythema nodosum
NSF is a fibrosing cutaneous disorder that has been increasingly recognized to have systemic manifestations. In the majority of NSF patients, symptomatic skin involvement is the initial presentation of the disease. Affected individuals may experience skin discoloration, induration, itchiness, ache, paraesthesia or burning sensation confined to the lower limbs. This will be followed by hardening and thickening of the skin of the extremities and trunk, often resulting in flexion contractures . Histologically NSF is characterised by an increased in spindle-shaped dermal cells, with CD 34 positive and procollagen I fibrocytes deposition in the dermis. This dual positivity (CD34 and procollagen I) is characteristic of the so-called “circulating fibrocytes,” of bone marrow origin . The common link to all patients developing NSF is the history of renal impairment and gadolinium-based contrast agent (GBCA) exposure. We present here a case whereby the initial presentation of NSF mimics the skin histology of erythema nodosum before manifesting with all the usual clinical and histopathological features of NSF.
Unfortunately, despite dialysis treatment intensification, she succumbed to cardiac arrhythmia.
Nephrogenic systemic fibrosis (NSF) is a progressive, potentially debilitating multi-organ system fibrosing disease related to exposure of the gadolinium-based contrast agents (GBCA) used in magnetic resonance imaging in patient with kidney failure . NSF affects patients in advanced stage of chronic kidney disease (CKD).
Clinically, NSF varies in its manifestations from patient to patient and over time. Based on a NSF literature encompassing a total of 130 reported patients, the earliest lesions frequently appeared in the lower extremities (85%), followed by the upper extremities (66%) and the trunk (23%) . The skin involvement is often symmetrical and bilateral. The usual initial presenting features were skin discoloration, induration, itchiness, ache and non-specific neuropathic symptoms confined to the lower limbs. Insomnia and transient, diffuse alopecia has also been described in the early stages. The predominant symptom at the later stage was symmetrical skin stiffness of the extremities with or without restricted joint motion .
NSF was previously known as nephrogenic fibrosing dermopathy (NFD) and dialysis-associated systemic fibrosis . It was originally named NFD since it was originally thought that the lesions were limited to the skin, it is now well documented that these lesions extend beyond the dermis and can involve joints, deeper structures such as muscle, lungs and heart.
The risk of developing NSF in a patient with severe kidney impairment following exposure to GBCA is roughly 4% regardless of gender, race or age . The onset between initial exposure to the GBCAs and the diagnosis of NSF can vary between 2 months to 18 months. Acute kidney injury, thromboembolic event, infection, malignancy and high dose erythropoietin usage are some of the risk factors that predisposed to NSF. Increasing cumulative gadodiamide exposure, high dose epoetin-b treatment, and higher serum concentrations of ionized calcium and phosphate increase the risk of gadodiamide-related NSF in CKD patients .
Gadodiamide has a half-life of 1.3 h in a healthy person. The half-life will increase to 10 h in patient with CKD stage 3b with estimated glomerular filtration rate (eGFR) of 20 to 40 mL/min, and this will further prolong to 34 h in patients with end-stage renal disease (ESRD). For patients with ESRD, the half-life is reduced markedly to between 1.9 to 2.6 h if haemodialysis procedure is done following the administration of gadolinium .
GBCA is made up of Gd3+ ion chelated by a proprietary ligand . Each of the available agents has a small tendency for the Gd3+ ion to separate from its ligand . Free Gd3+ ion is theoretically available to interact with other negatively charged substrates. These free gadolinium ions deposition in the dermis or surrounding tissue will results in tissue inflammation and fibrosis. Hence the risk of NSF increases with the severity of CKD. The risk ranges from 2.5–5% in patients with CKD 5 to virtually unheard of in non-dialysis patients . Patients on peritoneal dialysis (PD) has a higher incidence of NSF when compare to haemodialysis as the rate of clearance of CBGAs are much slower in PD.
EN is thought to be some form of hypersensitivity reaction. It may be idiopathic in origin or associated with underlying systemic diseases or drug therapies. Our patient has post-streptococcal like infection with EN changes demonstrated in the skin histology soon after she was being exposed to gadolinium. In our part of the world, EN is commonly associated with streptococcal infection. However, the findings of EN in the initial skin biopsy could also represent the early manifestation of NSF . In NSF, the skin may be variably affected with subtle, superficial papules and plaques, deeper dermal or subcutaneous induration. The most frequently seen lesions reported were plaques (58%), papules (32%) and nodules (17%) . Similar to ours, another retrospective single centre study has concluded that the risk of developing NSF is markedly increased when there is concurrent infection .
After exposure to GBCAs, the time of onset of NSF ranges from a few days to 6 months . In almost all of the cases, NSF is chronic and unremitting in nature. Joint contractures can be so debilitating that patients become wheelchair-bound within days to weeks after onset of the disease . Interestingly, our patient has symptoms of migratory joint paints, fever and malaise soon after being exposed to gadolinium. Although there has not been any report in the literature regarding the occurrence of acute systemic inflammatory reaction after receiving intravenous contrast, we are still incline to think that the patient’s symptoms are sequelae of gadolinium exposure rather than a true EN disease.
In our case, the possible differentials for thickening and hardening of the skin overlying the limbs and trunk involved a variety of other disorders, such as systemic sclerosis (scleroderma), scleromyxedema, eosinophilic fasciitis and calciphylaxis . The temporal history of gadolinium exposure in an advanced CKD patient coupled with tissue histopathological features of NSF can distinguished among them .
Unfortunately, there is no effective treatment available to treat NSF. Various trials involving corticosteroid, plasmapheresis, thiosulfate, methotrexate has been tried with no promising results . The mainstay of the management is to provide continuous medical and psychological support to the patient and family. Occupational and physiotherapy to optimize the affected joints functionality are of utmost importance. Avoidance of gadolinium appeared to be the major preventive measure for NSF.
In this case, the administration of GBCA has clearly not benefited the patient. Retrospectively, alternative imaging method should have been considered. Once considered to be safe to be used in the setting of renal disease, the US Food and Drug Administration and the European Medicines Agency has prohibited the use of three types of gadolinium based agents (Magnevist, Omniscan, and Optimark) in the setting of renal diseases in 2010 . Our unfortunate incident happened in early 2012. It is not the intention of this paper to apportion blame as to why gadodiamide is being administered inadvertently but to ensure such episode will not occur again. It could be due to the fact that since no cases of NSF have been reported in our country before, there may be a misconception among the health professionals that GBCAs are safer than contrast agent used in computer tomography. Thus far, various inter departments dialog had ensued and agreement has been made that no GBCAs should be given to patients with moderate to severe kidney disease. The next-of-kind of the patient had been duly informed of the adverse event and updated continuously throughout the incident.
Our experience with this patient shows that the early skin features of NSF can be histopathologically indistinguishable from EN. Besides, the acute inflammatory like reaction experienced by the patients post gadodiamide has further aroused the suspicion of EN. Nevertheless, we believe that the patient’s presentation is within the spectrum of manifestation of NSF. We hope by highlighting this case, we can avoid the potential pitfall of missing early phase of NSF in CKD patients who received CBGA.
Availability of data and materials
All data generated or analysed during this study are included in this published article.
FKW and CTSL participate in the literature review, data collection manuscript writing and reviewing. Both authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Family next of kin had given consent for the data and picture used.
The authors declare that they have no competing interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol. 2008 Mar;69(3):161–8.View ArticlePubMedGoogle Scholar
- Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25(4):358.View ArticlePubMedGoogle Scholar
- Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66(2):191–9.Google Scholar
- Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy withsystemic involvement. Arch Dermatol. 2003;139(7):903–6.View ArticlePubMedGoogle Scholar
- Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35–2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004;351:2219.View ArticlePubMedGoogle Scholar
- Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491.View ArticlePubMedGoogle Scholar
- Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Investig Radiol. 2007;42:139–45.View ArticleGoogle Scholar
- Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging. 2007;2:199–205.View ArticlePubMedGoogle Scholar
- Chrysochou C, Power A, Shurrab AE, et al. Low risk for Nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010;5(3):484–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Elizabeth N, Hu S, Leslie RB. Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. Am Acad Dermatol. 2008;58:149–50.View ArticleGoogle Scholar
- Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol. 2008;190:1069.View ArticlePubMedGoogle Scholar
- The International Center for Nephrogenic Fibrosing Dermopathy Research http://www.icnfdr.org. Accessed 8 Jan 2017.
- Edsall LC, English JC III, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol. 2004;31:247–53.View ArticlePubMedGoogle Scholar
- Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32:484.View ArticlePubMedGoogle Scholar
- Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238.View ArticlePubMedPubMed CentralGoogle Scholar
- U.S Food and Drug Administration. 2010. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. https://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed 24 Apr 2017.